Many of today's equestrian businesses still use, in terms of management and training, methods based on insights from the last century. If we, as a profession, want to continue supporting equestrian sports in a positive way over the next decade, it is essential to revise these methods and provide horse owners with sufficient practical tools to do so.
Nutrition plays a vital role within managing horse welfare; a proper ration is essential. Although
HorStem is the first registered veterinary medicine based on mesenchymal stem cells obtained from the umbilical cord of horses. Stem cells reduce lameness in horses with mild to moderate degenerative joint disease (OA).
It is a ready-to-use, sterile, injectable suspension for intra-articular use in horses. Each vial contains 15 million active stem cells, more than enough to achieve the minimum effective dose in the joint regardless of the degree of inflammation or the patient's immune system status.
The mechanism of action of HorStem is illustrated in the figure on the right. Mesenchymal stem cells are activated in the synovium by inflammatory cytokines. In response, they secrete anti-inflammatory cytokines such as Prostaglandin E2 (PGE2).
While PGE2 is primarily known for its pro-inflammatory effects, it also plays a crucial role in regulating inflammation. It is one of the major immunomodulatory cytokines in the body.
When applied to horses with OA, HorStem inhibits T-cell proliferation, reduces the production of pro-inflammatory cytokines like TNF-alpha, and decreases the presence of matrix metalloproteinases (MMPs) that contribute to the breakdown of cartilage's extracellular matrix. Studies have shown that these effects are mediated by PGE2. (1)
Moreover, umbilical cord-derived mesenchymal stem cells stimulate the production of anti-inflammatory cytokines such as IL-4, IL-5, IL-10, and TGF-beta. As the inflammatory response ceases
Expansion adds new countries to Grovet's existing PulseVet distribution coverage and enables launch of the TRUFORMA® equine platform in Europe
ANN ARBOR, MI / ACCESSWIRE / October 3, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the expansion of its distribution partnership in Europe with Grovet, a leading equine-focused veterinary distributor.
The terms of the updated agreement offer Grovet equine distribution rights for Zomedica's equine PulseVet® and TRUFORMA product platforms throughout most of Europe. Grovet will exclusively distribute these equine products in 27 countries, including Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,
Meet our team at...
Oct. 10 to 11
Oct. 24 to 25
Oct. 26 to 27
31 oktober t/m 2 november
Sports Medicine and Rehabilitation Days - NL
We look forward to meeting you!
Pro-Stride, Restigen et CenTrate sont des dispositifs médicaux qui permettent de transformer le sang du cheval en solutions thérapeutiques. En moins de 30 minutes, des solutions de protéines autologues (APS), des PRP et des concentrés d'aspirats de moelle osseuse peuvent être préparés. Le système est adapté à une utilisation ambulatoire et ne nécessite pas d'incubation. Le système est fermé ce qui en fait un processus sûr avec un risque minimal de contamination.
Le Restigen PRP est principalement utilisé
Oxtra DD is an antibiotic for the treatment of infections caused by oxytetracycline-sensitive organisms. Oxtra DD is a solution for injection for horses, cattle, sheep, pigs, dogs and cats.
Oxtra DD is a bacteriostatic antibiotic with high bioavailability and a broad antibacterial spectrum of action covering both gram-positive and gram-negative bacteria. Oxtra DD gives good concentrations both in deep tissue and intracellularly.
Oxytetracycline inhibits protein synthesis in susceptible bacteria. It binds to the receptors on subunit 30S which prevents the addition of amino acids to the growing peptide chain, thereby inhibiting protein synthesis.
Oxtra DD can be administered intramuscularly every 24 hours thanks to its special formulation, either at low doses or at higher doses
At Grovet, we are driven to exceed equine veterinarian expectations and are constantly developing our product line to continue to optimize it. Our supplements for horses are of high quality and are formulated based on scientific evidence. Grovet offers a wide range of complementary feeds to support the management of sport horses, read more below.
For filling the horse's hoof when taking X-rays. Try it now!
Rediscover the classic with 30% discount!*
*This promotion is valid until July 19 2024
Available soon at Grovet; Oxtra DD
Oxtra DD is a bacteriostatic antibiotic with high bioavailability and a broad antibacterial spectrum that includes both gram-positive and gram-negative bacteria. Oxtra DD achieves effective concentrations both in deep tissues and intracellularly. Oxytetracycline inhibits protein synthesis in susceptible bacteria by binding to the receptors on the 30S subunit, preventing the addition of amino acids to the growing peptide chain, thereby halting protein synthesis.
Thanks to its special formulation, Oxtra DD can be administered intramuscularly every 24 hours, either in a low dosage or in a higher dosage for prolonged action (in cattle, sheep, and pigs). Unlike most injectable oxytetracyclines, Oxtra DD can also be safely administered intravenously.
Please check the SPC here:
